Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hillemanns

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2012
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyK H Baumann, A du Bois, W Meier, et al.
Vaccine|June 16, 2009
Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasiaD Pathirana, P Hillemanns, K-U Petry, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2020
Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort studyD Cibula, L Dostalek, P Hillemanns, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT studyF Trillsch, S Mahner, L Woelber, et al.
British Journal of Cancer|January 7, 2015
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT studyF Trillsch, S Mahner, E Vettorazzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trialP Harter, C Marth, M-A Mouret-Reynier, et al.
British Journal of Cancer|October 29, 2011
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer riskK N Stevens, M Garcia-Closas, Z Fredericksen, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2012
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyK H Baumann, A du Bois, W Meier, et al.
Vaccine|June 16, 2009
Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasiaD Pathirana, P Hillemanns, K-U Petry, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2020
Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort studyD Cibula, L Dostalek, P Hillemanns, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT studyF Trillsch, S Mahner, L Woelber, et al.
British Journal of Cancer|January 7, 2015
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT studyF Trillsch, S Mahner, E Vettorazzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trialP Harter, C Marth, M-A Mouret-Reynier, et al.
British Journal of Cancer|October 29, 2011
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer riskK N Stevens, M Garcia-Closas, Z Fredericksen, et al.
Pageof 11